Eli Lilly has requested Europe's drug regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said ...

Shares in pharmaceuticals giant Eli Lilly (LLY) were looking perkier today after it ramped up its battle to get a key ...

The drug is an oral beta secretase cleaving enzyme (BACE) inhibitor, which the companies plan to bring into phase 2/3 trials to test in patients with early Alzheimer's disease.

The drug had already failed in two phase 3 trials in 2012 – but Lilly pressed on with a third trial in mild Alzheimer’s after spotting a trend in the data suggesting an effect in a small group ...

European Committee Says Lilly Alzheimer's Drug Shouldn't Get Marketing Approval A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

The second U.S. drug shown to slow the progression of early Alzheimer's has arrived in Seattle-area clinics. One of the first ...

Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

A European health committee has rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, because of safety concerns about possible brain swelling and bleeding. Although the drug is already ...

Lilly said Friday that it hopes discussions about the drug continue with the agency ... that target one contributor to Alzheimer’s — sticky amyloid plaque buildup in the brain.